重组白介素2与顺铂治疗恶性胸腹水的疗效观察

目的：观察重组白介素（ｒＩＬ－２）与顺铂（ＤＤＰ）胸腹腔注入治疗恶性胸腹水的疗效。方法：对４５例恶性胸腹水患者应用ｒＩＬ－２与ＤＤＰ胸腹腔注入；对照组４０例患者采用ＤＤＰ做胸腹腔注入以做比较。结果：治疗组治疗恶性胸腹水总有效率８９％，其中胸水有效率达９０％，腹水有效率达８８％。ＤＤＰ对照组治疗恶性胸腹水总有效率７０％，其中胸水有效率达７２．２％，腹水有效率达６８．２％。结论：ｒＩＬ－２与ＤＤＰ联合应用治疗恶性胸腹水有显著的协同作用（Ｘ２＝４．７２，Ｐ＜０．０５），毒副反应小，见效快，能及时减轻患者的痛苦，是安全有效的方法。

Therapeutic evaluation of cisplation plus interleukin-Ⅱin malignant hydrothorax and ascites

Objective: To boserve therapeutic effectiveness of cisplatin plus interleukin-l in malignant hydrothorax and as-cites. Methos: In experimental group, 45 cases were injected interleukin-Ⅱ and cisplation into thoracic cavity or abdominalcavity once a week, 3-6 weeks as one cylce. As a control group,40 cases were injected cisplation alone in the same way. Re-sults: The total effective rate in experimental group was 89% ,about 90% in hydrothorax,89% in ascites. The rates in controlgroup were 70%, 72.2 % and 68.2 %, respectively. Conclusion: Interleukin-Ⅱ and cisplatin were synergistic in treating ma-lignatn hydrothorax and ascites. Statistic management was significant(χ2=4.72, P＜0.05). It has practical value of extendingto clinical appliction.